Medicare Advantage Leads: The 2026 Acquisition Guide

Medicare Advantage lead buying requires separate checks for source quality, permission to contact, Scope of Appointment (SOA), plan marketing and enrollment documentation. The April 6, 2026 CMS final rule became effective June 1, with its new marketing policies applicable to contract-year 2027 marketing beginning October 1, 2026. This substantive October update preserves the original May publication date. It is informational, not legal advice or a compliance certification.

The four MA lead types you'll actually buy

AEP, OEP, and the year-round window

MA lead supply concentrates in three windows. Plan accordingly or you'll either overpay for AEP or starve in the off-season.

• AEP (October 15–December 7): Annual enrollment period. Forecast capacity and obtain current product quotes rather than assuming a fixed seasonal price or outcome.
• Medicare Advantage OEP (January 1–March 31): Applies to eligible people already enrolled in Medicare Advantage. CMS restricts knowingly targeting OEP marketing to this audience; an election opportunity is not permission for unsolicited outreach.
• Initial and Special Enrollment Periods: Eligibility and permitted elections depend on the beneficiary and current rules. Turning 65 generally involves an initial enrollment window, not automatically an SEP. Verify each qualifying event and plan option.

Evaluate current pricing without invented benchmarks

No verified market dataset supports the former price ranges, median CPLs, close rate or target CPP in this guide. Obtain current written quotes for the specified source, geography, qualification and delivery. These are not OneLife prices. Calculate cost per issued policy from your own spend and verified outcomes, including chargebacks and producer costs; no conversion result is guaranteed.

CMS marketing rules that govern your lead funnel

CMS marketing guidelines are non-negotiable. Three rules drive most of the lead-level compliance work:

1. TPMO disclaimer. Use the applicable CMS wording based on whether the TPMO represents all organizations in the service area, including the required organization and plan counts. For CY 2027 marketing beginning October 1, 2026, verbally convey it during sales calls before discussing any benefits, rather than applying the superseded first-minute timing. Apply the specified website, electronic-communication and marketing-material placements; a generic fragment is not a complete disclaimer.
2. Scope of Appointment. Before a personal marketing appointment, agree upon and record the scope with the beneficiary; in-person appointments require written SOA. For CY 2027 marketing beginning October 1, 2026, CMS removed the fixed 48-hour wait, not SOA itself. A valid existing SOA can cover contacts within its scope; a new plan year or expanded scope needs appropriate documentation. Follow plan retention instructions and applicable record rules.
3. Recording. For the CY 2027 marketing transition beginning October 1, 2026, covered TPMO marketing and sales calls, including web-call audio, must be recorded in full and retained at least six years. Keep audio for the first three years; years four through six may use audio or complete, accurate transcripts. Enrollment portions and records retain separate ten-year requirements. Do not shorten legacy records or SOA retention based on this limited change.

Permission to contact, SOA and TPMO-to-TPMO data-sharing permission are distinct. Unsolicited telephone solicitation is not authorized simply because a contact is commercially available. Personal beneficiary data collected by a TPMO for Medicare marketing or enrollment may be shared with another TPMO only with prior express written consent identifying each receiving entity and permitting a separate accept/reject choice. Do not infer that the vacated FCC one-to-one rule removed this CMS requirement. Apply plan contracts, privacy safeguards and separate calling/recording laws as well.

The producer workflow that wins AEP

Pre-call review

Confirm the source, lawful permission to contact, available non-sensitive information and licensed producer fit. A marketing opt-in does not authorize unrestricted health-data collection. Obtain necessary provider or medication details only through an appropriately authorized, secure needs-assessment process; do not require every lead record to contain sensitive information.

Opening and scope

For the October 1, 2026 CY 2027 marketing transition, convey the applicable TPMO disclaimer during sales calls before discussing benefits, and confirm the agreed SOA before the personal marketing appointment. Where the TPMO lead-generation duties apply, disclose that the beneficiary's information will be provided to a licensed agent for future contact and, for a transfer, that the beneficiary is being transferred to an agent who can enroll them. These disclosures under sections 422.2274(g)(3) and 423.2274(g)(3) do not replace the separate per-TPMO written sharing consent under (g)(4). Permission to contact, SOA and data-sharing permission are distinct; inbound origin is not a blanket exemption.

Needs-based plan comparison

Use a needs-based comparison of appropriate plan options and explain material costs, drug coverage and network restrictions. Do not force the discussion into a fixed number of plans or a 12–14-minute sales target; the beneficiary must have adequate time for an informed choice.

Enrollment at the beneficiary's pace

Follow the applicable plan enrollment process and document the beneficiary's request and attestation. Enrollment call portions are separate from marketing/sales recording retention. For a combined call that cannot be reliably separated, keeping the full recording for the longer applicable period is a conservative operational approach, not a new six-year enrollment rule.

Chargebacks: the silent margin killer in MA

Compensation recovery depends on applicable CMS rules, plan contracts and the circumstances of disenrollment. Review current plan instructions; do not treat a generic chargeback formula or reduction percentage as universal. Consider these service practices without promising a measured outcome:

• Where necessary and authorized, verify medication and pharmacy coverage through secure plan tools. No ranked cancellation statistic is claimed here.
• Confirm relevant provider participation using current plan information and explain verification limits.
• Consider appropriate post-enrollment service follow-up, subject to permitted contact and plan instructions. A seven-day or thirty-day cadence is an optional practice, not a substantiated 30–40% chargeback reduction.

Common mistakes in Medicare lead programs

• Buying "Medicare" leads without specifying MA vs. Med Sup. They convert differently and need different producers.
• Starting a personal marketing appointment without an appropriately agreed and recorded SOA, or assuming a live transfer supplies permission to contact and sharing consent automatically.
• Pitching the high-commission plan over the best-fit plan. Chargebacks eat the margin and CMS audits the pattern.
• Applying six-year marketing/sales retention to enrollment records, SOAs or legacy calls without reviewing applicable requirements, plan instructions and holds.
• Treating a seven-day or thirty-day service follow-up cadence as a CMS mandate or a guaranteed way to prevent disenrollment. Follow permitted contact, beneficiary needs and applicable plan instructions.

Actionable takeaways

1. Plan AEP capacity early and verify current written source and delivery specifications; no universal seasonal price multiplier is supported.
2. Demand TPMO-compliant ad creatives and consent flows from every supplier.
3. Document SOA before personal marketing appointments; verify existing scope, applicable plan year, permission to contact and separate TPMO-sharing consent.
4. Evaluate appropriate post-enrollment service follow-up under permitted contact and plan instructions; no fixed cadence or chargeback reduction is guaranteed.
5. Track CPP after chargebacks, not before. The honest number is the net one.